Image of the Month

A view of the Badab-e Surt. Mazandaran Province in northern Iran. The stepped travertine terrace formations that created over thousands of years as flowing water from two mineral springs (Photo by :Anahita Sadeghi MD)


The collection of articles appearing in the current book consists of manuscripts on the history of medicine in Iran, initially published from 1998 to 2014 in the “Archives of Iranian Medicine” (AIM). These articles are categorized into four separate parts, based on their subjects: Part 1) Ancient Times, Medieval Period, Part 2) Contemporary Medicine, Part 3) Outstanding Physicians and Part 4) Historical Background of Fatal Diseases in Iran. These 73 manuscripts have now been compiled in a 446 pages book for those who are interested in the history of Iranian medicine.

Since the Archive of Iranian Medicine (AIM) journal presents as Open Access monthly, online periodical from May 2013, thus dear readers may refer to the journal website ( for free downloading of the published papers.

AIM Office

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports®(JCR®) 2012 is 1.222.

Selected Article
Comparison of 25 µg Sublingual and 50 µg Intravaginal Misoprostol for Cervical Ripening and Labor: A Randomized Controlled Equivalence Trial 1

Authors’ affiliations: 1Reproductive Health Research Center, Guilan university of Medical Sciences, Guilan, Iran. 2Department of neonatology, Guilan university of Medical Sciences, Guilan, Iran. 3Vice-chancellorship Guilan University of Medical Sciences, Guilan, Iran.

·Corresponding author and reprints: Forozan Milani MD, Reproductive Health Research Center, Department of Obstetrics and Gynecology, Al-zahara Hospital, Guilan University of Medical Sciences, Namjo Street, Rasht, Guilan, Iran.

Tel: +98-911-131-5936, E-mail:

Accepted for publication: 23 July 2014


Pubmedxml   Download PDF Fulltext
Authors: Seyedeh Hajar Sharami1, *Forozan Milani2, Roya Faraji3, Kobra Bloukimoghadam4, Fatemeh Salamat5, Salma Momenzadeh6, Hanan Ebrahimi7,
Keywords: Cervical ripening, labor, misoprostol

BACKGROUND: Sublingual misoprostol, used for labor induction, produces earlier and higher peak plasma concentrations of misoprostol than vaginal or rectal misoprostol. The sublingual route could be expected to be more effective and safer than the vaginal route and by avoiding a direct effect on the cervix, it might reduce the risk of uterine hyperstimulation and be safer. This study aimed to compare the efficacy of 25-µg sublingual misoprostol with 50-µg intravaginal misoprostol for cervical ripening prior to labor induction in primiparous women.
METHODS: In a double-blind, parallel randomized controlled equivalence trial, we recruited 131 primiparous women at 36–42 weeks of gestation requiring labor induction who referred to Alzahara hospital in Rasht, Iran. The women were randomly assigned to receive 25-µg sublingual misoprostol with vaginal placebo (n = 63) or 50-µg intravaginal misoprostol with sublingual placebo (n = 63). The dose was repeated every 4 h (maximum 4 doses). The primary outcome was the interval from the start of induction to vaginal delivery.
RESULTS: There were no significant differences between the two groups with regard to the interval from the start of induction to vaginal delivery(13.2 ± 3.07 h in the vaginal group vs. 13.1 ± 3.46 h in the sublingual group), duration of active phase, Bishop Scores after 4h, and rate of the vaginal delivery under 12 h. Also, the rate of hyperstimulation, tachysystole, type of delivery, cause of cesarean section, Apgar scores less than 7 and admission to the NICU were similar in these two groups. The mean dose of misoprostol applied was significantly lower in the sublingual group (P = 0.001).
CONCLUSION: Sublingual administration of 25-µg of misoprostol appears to be as effective as 50 µg intravaginal misoprostol for cervical ripening and labor induction.
Trial Registration: This trial has been registered under IRCT 38903131096N3

ISSN:1029-2977       Article type:Original
Useful Links
Privacy Statement    |    Terms Of Use Copyright 2009 by Academy of Medical Sciences of the I.R. Iran